Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.22.2.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Consolidated Statements of Operations and Comprehensive Loss    
Revenues $ 2,383 $ 2,371
Cost of goods sold 216 1,462
Gross profit 2,167 909
Operating expenses:    
Research and development 17,729 9,989
General and administrative (related party of $250 and $1,587) 34,128 22,031
Total operating expenses 51,857 32,020
Operating loss (49,690) (31,111)
Other income (expense):    
Interest expense (related party of $810 and $2,446) (1,412) (2,454)
Interest income 178 140
Royalty income 7 12
Settlement income   10,200
Forgiveness of note payable and accrued interest - SBA loan 607  
Other 6  
Total other income (expense) (614) 7,898
Consolidated net loss (50,304) (23,213)
Net loss attributable to noncontrolling interest 1 6
Net loss attributable to iBio, Inc. (50,303) (23,207)
Preferred stock dividends (88) (260)
Net loss attributable to iBio, Inc. stockholders (50,391) (23,467)
Comprehensive loss:    
Consolidated net loss (50,304) (23,213)
Other comprehensive loss - unrealized loss on debt securities (150) (29)
Other comprehensive loss - foreign currency translation adjustments   (1)
Comprehensive loss $ (50,454) $ (23,243)
Loss per common share attributable to iBio, Inc. stockholders - basic $ (5.78) $ (3.00)
Loss per common share attributable to iBio, Inc. stockholders - diluted $ (5.78) $ (3.00)
Weighted-average common shares outstanding - basic 8,721 7,825
Weighted-average common shares outstanding - diluted 8,721 7,825